#US Acute Myeloid Leukemia Market trends

[kenresearch1]

The Transformative Growth of the US Acute Myeloid Leukemia Market

Buy Now

What is the Size of US Acute Myeloid Leukemia Industry?

US Acute Myeloid Leukemia Market is expected to grow at a CAGR of ~ % in 2022 and is expected to reach ~USD Mn by 2028. The US Acute Myeloid Leukemia market is the rapid advancement in precision medicine and targeted therapies. The emergence of innovative treatments tailored to the genetic and molecular characteristics of individual AML patients has transformed the treatment landscape. Targeted therapies, such as FLT3 and IDH inhibitors, capitalize on specific genetic mutations driving AML, resulting in higher response rates and improved outcomes compared to traditional approaches.

Precision medicine's ability to identify the most effective treatment for each patient not only enhances therapeutic efficacy but also reduces unnecessary treatments, mitigating side effects and improving overall quality of life. This paradigm shift is bolstered by technological progress in molecular profiling techniques like next-generation sequencing, allowing for accurate genetic profiling and treatment customization.

Furthermore, regulatory support and accelerated approval pathways for targeted therapies have expedited their availability to patients. Pharmaceutical companies' increasing investment in research and development of novel agents, along with collaborations between academia and industry, leads to grow this market even more.

Click here to Download a Sample Report

US Acute Myeloid Leukemia Market by treatment type

The market is segmented by Treatment type into Chemotherapy, Targeted Therapy, Hormone Therapy, Immunotherapy and Others. Targeted Therapy is the dominant segment in the US Acute Myeloid Leukemia market in 2022. Specialty Centers, dedicated to the diagnosis, treatment, and management of specific medical conditions like AML, offer a concentrated and specialized approach to patient care. Their dominance in the AML market is driven by their unique capabilities to provide comprehensive and tailored treatments that address the complex needs of AML patients.

US Acute Myeloid Leukemia Market by end -user industry

The market is segmented by End-User into Hospitals, Homecare, Specialty Centers, Pharmacies and Others. Among these, Specialty Centers are the dominant End-User in the US Acute Myeloid Leukemia market in 2022. Specialty centers have a higher level of expertise and experience in treating specific types of cancer, including acute leukemia. They typically have specialized medical professionals, including hematologists and oncologists, who are well-versed in the latest treatment protocols and research. These centers are equipped with state-of-the-art diagnostic and treatment facilities that are specifically tailored to the needs of leukemia patients. This can include advanced imaging technologies, specialized laboratories, and access to cutting-edge therapies.

Click here to Download a Custom Report

US Acute Myeloid Leukemia companies market by Region

The US Acute Myeloid Leukemia market is segmented by Region into North, South, East, West. The dominance region is North in the US Acute Myeloid Leukemia Market in 2022. the North region often benefits from a higher level of funding for medical research, including AML. Federal funding agencies, private foundations, and pharmaceutical companies frequently channel resources into institutions within this region, allowing for greater research capabilities and clinical trials infrastructure.

Competition Scenario in US Acute Myeloid Leukemia Market

The US acute myeloid leukemia market was characterized by the presence of several prominent pharmaceutical companies and biotechnology firms striving to establish their presence and gain a competitive edge.

Larger corporations, smaller biotechnology companies making significant contributions to the AML landscape. Companies like Agios Pharmaceuticals and Daiichi Sankyo were gaining attention for their novel therapies targeting AML-associated mutations. These players are often at the forefront of introducing precision medicine approaches to AML treatment, taking advantage of advancements in genetic profiling and molecular diagnostics.

The competition is further intensified by research collaborations and partnerships between pharmaceutical companies, academic institutions, and research organizations. These collaborations aimed to combine resources, expertise, and insights to accelerate the development of effective therapies.

What is the Expected Future Outlook for the Overall US Acute Myeloid Leukemia market?

The US Acute Myeloid Leukemia market was valued at USD ~Million in 2022 and is anticipated to reach USD ~ Million by the end of 2028, witnessing a CAGR of ~% during the forecast period 2022- 2028. Pharmaceutical companies have been actively researching and developing novel therapies for Acute Myeloid Leukemia, with a focus on improving patient outcomes and reducing the side effects associated with traditional treatments like chemotherapy.  The approval of new drugs, such as FLT3 and IDH inhibitors, has offered fresh therapeutic avenues for specific subsets of Acute Myeloid Leukemia patients with genetic mutations.

The future outlook for the US Acute Myeloid Leukemia market is anticipated to be influenced by a combination of factors including advancements in treatment options, evolving regulatory landscapes, and a growing understanding of the molecular basis of Acute Myeloid Leukemia. The market has been witnessing a shift towards personalized medicine, with increasing emphasis on targeted therapies and precision medicine approaches.

Furthermore, the integration of innovative technologies like next-generation sequencing (NGS) has enhanced our understanding of Acute Myeloid Leukemia’s molecular complexities, allowing for better patient stratification and treatment selection. This trend toward molecular profiling and personalized treatment regimens is likely to continue shaping the market landscape.

However, challenges persist. Despite progress, Acute Myeloid Leukemia remains a difficult-to-treat disease with a high relapse rate. Overcoming drug resistance and developing effective strategies for patients who do not respond well to existing therapies remain critical areas of focus.

Additionally, the cost of novel therapies and access to these treatments could also impact their adoption and availability. The regulatory environment, including expedited pathways for drug approvals, continue to influence market dynamics.

[health-views-updates]

Advances in Leukemia Therapeutics: Innovations and Emerging Trends

The Evolving Landscape of Leukemia Treatment

Leukemia, a group of malignancies that affect the blood and bone marrow, continues to challenge the medical community with its complexity and variability. Recent years have seen significant strides in leukemia therapeutics, driven by advancements in drug development, personalized medicine, and novel therapeutic strategies. These innovations are transforming treatment paradigms, offering new hope to patients and paving the way for more effective and targeted therapies.

Breakthroughs in Drug Development

One of the most significant advancements in leukemia therapeutics is the development of targeted therapies. Unlike traditional chemotherapy, which indiscriminately kills rapidly dividing cells, targeted therapies are designed to attack specific molecules involved in cancer progression. For instance, tyrosine kinase inhibitors (TKIs) like imatinib, dasatinib, and nilotinib have revolutionized the treatment of chronic myeloid leukemia (CML). These drugs target the BCR-ABL protein, a key driver of CML, leading to improved outcomes and reduced side effects compared to conventional treatments.

In addition to TKIs, the approval of novel agents such as venetoclax has marked a significant leap forward. Venetoclax targets the BCL-2 protein, which is often overexpressed in leukemia cells, thereby promoting their survival. By inhibiting BCL-2, venetoclax enhances the effectiveness of chemotherapy and has shown promise in treating acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).

Advances in Immunotherapy

Immunotherapy is another area where substantial progress has been made. Chimeric antigen receptor (CAR) T-cell therapy represents a groundbreaking approach, especially for acute lymphoblastic leukemia (ALL) and some cases of CLL. This therapy involves modifying a patient's T-cells to express a CAR that targets leukemia-specific antigens. The modified T-cells are then reintroduced into the patient’s body, where they identify and destroy leukemia cells.

Recent studies have demonstrated the efficacy of CAR T-cell therapies, leading to impressive remission rates in patients with refractory or relapsed leukemia. However, this approach is not without challenges. The risk of cytokine release syndrome (CRS) and neurotoxicity remains a concern, and ongoing research aims to enhance the safety and effectiveness of CAR T-cell therapies.

The Leukemia Therapeutics Market size was USD 16 Billion in 2023 and is expected to Reach USD 27.28 Billion by 2031 and grow at a CAGR of 6.9% over the forecast period of 2024-2031.

Precision Medicine and Genetic Insights

The era of precision medicine has ushered in a new approach to leukemia treatment, with a focus on tailoring therapies based on individual genetic profiles. Advances in genomic sequencing have identified specific mutations and genetic alterations associated with different types of leukemia. For example, mutations in the FLT3 gene are common in AML, and targeted inhibitors like midostaurin are being used to address these mutations.

Similarly, research into the genetic underpinnings of CLL has led to the development of drugs that target specific mutations or pathways involved in the disease. By understanding the unique genetic landscape of each patient’s leukemia, clinicians can select the most effective therapies and potentially improve treatment outcomes.

Future Directions and Challenges

While the progress in leukemia therapeutics is promising, several challenges remain. The high cost of novel therapies, including CAR T-cell treatments, poses a significant barrier to access for many patients. Additionally, the development of resistance to targeted therapies and immunotherapies requires ongoing research to develop new and effective treatment options.

Looking ahead, researchers are exploring combination therapies, novel drug targets, and personalized approaches to overcome these challenges. The integration of artificial intelligence and machine learning in drug discovery and treatment planning holds the potential to further accelerate progress in leukemia therapeutics.

Conclusion

The field of leukemia therapeutics is undergoing a transformative phase, with innovations in drug development, immunotherapy, and precision medicine leading the way. These advancements are not only enhancing treatment outcomes but also offering new hope to patients. As research continues to evolve, the focus will remain on overcoming current challenges and pushing the boundaries of what is possible in the fight against leukemia.

[priteshwemarketresearch]

Olutasidenib Market Research Trends Analysis by 2024-2034

Olutasidenib Market Introduction:

Olutasidenib is emerging as a pivotal drug in the oncology field, targeting cancers with specific genetic mutations. Developed to inhibit the mutant form of the isocitrate dehydrogenase 1 (IDH1) enzyme, olutasidenib offers a targeted approach for treating cancers driven by IDH1 mutations, particularly acute myeloid leukemia (AML).

Unlock your exclusive sample PDF now:

Market Trends

Increasing Adoption in Clinical Practice: Olutasidenib's clinical trials have shown promising results, particularly in treating acute myeloid leukemia (AML) and other hematologic malignancies. The drug's effectiveness in targeting IDH1 mutations has garnered interest from oncologists, leading to its gradual adoption in clinical settings. As more data becomes available, the use of olutasidenib is expected to become more widespread, further driving market growth.

Growing Pipeline of IDH1-Mutant Cancers: The olutasidenib market is benefiting from an expanding pipeline of IDH1-mutant cancers. Research is ongoing to evaluate the drug's efficacy in various cancer types beyond AML, including solid tumors. This broadening scope is likely to enhance market potential and create new opportunities for pharmaceutical companies.

Increasing Investment and Partnerships: Pharmaceutical companies are investing heavily in the development and commercialization of targeted therapies like olutasidenib. Strategic partnerships and collaborations are becoming more common as companies seek to leverage each other’s strengths in research, development, and market access. These alliances are crucial for accelerating the drug’s availability and expanding its reach.

Opportunities in the Olutasidenib Market

Expanding Indications: While olutasidenib is currently approved for specific indications, there is significant potential for expanding its use. Ongoing research is exploring its effectiveness in additional cancer types and stages. Successfully gaining approval for these new indications could substantially increase the drug's market share.

Global Market Expansion: As the drug continues to demonstrate its efficacy, there is a growing opportunity for global market expansion. Different regions may have varying rates of IDH1-mutant cancers, which could influence the drug's market dynamics. Companies that successfully navigate regulatory pathways in diverse markets will have a competitive advantage.

Personalized Medicine: The rise of personalized medicine is a key factor driving the olutasidenib market. With a focus on precision oncology, treatments are increasingly tailored to the genetic profiles of individual patients. Olutasidenib’s targeted approach aligns well with this trend, offering the potential for more effective and personalized cancer treatment.

Olutasidenib Market  Segments

by Type

Generic Olutasidenib

Branded Olutasidenib

       by Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Olutasidenib Market  Key Market Players

AbbVie Inc.

Olutasidenib Industry: Regional Analysis

North America Market Forecast

With a Olutasidenib Market share of more than 47%, North America leads the global olutasidenib industry in terms of revenue generation. Because of its sophisticated healthcare system and large R&D expenditures, North America is one of the top markets for olutasidenib. Novel treatments are highly sought for due to the high incidence of acute myeloid leukemia (AML) and the large number of clinical studies carried out in the United States and Canada. Market potential is further enhanced by this region's established healthcare infrastructure and emphasis on innovative treatments.

European Market Data

Europe's market for olutasidenib is bolstered by its extensive clinical research endeavors and strong healthcare infrastructure. Demand is increased by the high cancer incidence rates and favorable regulatory regimes found in nations like Germany, France, and the UK. The potential for Olutasidenib's expansion in Europe is enhanced by the region's investment in cancer research and development, as well as the enhancement of patient access to innovative medicines.

Challenges and Considerations

High Development Costs: Developing and bringing a novel drug to market involves substantial investment. The costs associated with clinical trials, regulatory approvals, and market access can be significant. Companies must carefully manage these expenses to ensure a favorable return on investment.

Competition and Market Saturation: The oncology market is highly competitive, with numerous therapies targeting similar pathways. As more drugs enter the market, olutasidenib will need to demonstrate clear advantages in efficacy and safety to maintain its competitive edge.

Regulatory Hurdles: Navigating the regulatory landscape can be complex and time-consuming. Companies must adhere to rigorous standards to gain approval for new indications and international markets. Successfully overcoming these regulatory hurdles is essential for maximizing market potential.

Olutasidenib and Clinical Trials

Before its approval, Olutasidenib Market  underwent rigorous clinical trials to evaluate its safety and efficacy. These studies demonstrated promising results in terms of:

Response Rate: A significant number of patients experienced complete or partial remission of their AML.

Survival: Patients treated with olutasidenib showed improved overall survival compared to standard treatment options.

Key benefits of olutasidenib include:

Targeted therapy: Specifically addresses the underlying genetic cause of AML in patients with the IDH1 mutation.

Oral administration: Convenient and patient-friendly compared to traditional intravenous chemotherapy.

Improved outcomes: Demonstrated effectiveness in clinical trials, leading to increased response rates and improved survival.

Future Outlook

The future of the olutasidenib market appears promising, with ongoing research and development efforts poised to enhance its therapeutic potential. As the drug continues to show efficacy in clinical trials and expands its indications, it is likely to become a cornerstone of treatment for IDH1-mutant cancers. Additionally, advancements in personalized medicine and global market expansion will further drive growth.

Conclusion,

Olutasidenib represents a significant advancement in targeted cancer therapy. Its market trajectory will be shaped by continued research, strategic partnerships, and the evolving landscape of oncology. For investors, healthcare professionals, and patients alike, the Olutasidenib Market  offers a glimpse into the future of personalized and effective cancer treatment.

[cmipooja]

Global Dasatinib Drugs Market Is Estimated To Witness High Growth Owing To Increasing Demand for Targeted Cancer Therapies

The global Dasatinib Drugs Market is estimated to be valued at US$ 4.35 billion in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights. Market Overview: Dasatinib is an oral medication used for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is classified as a tyrosine kinase inhibitor and works by blocking the action of abnormal proteins that signal the growth of cancer cells. The advantages of dasatinib include its high efficacy in treating CML, ability to target specific cancer cells, and reduced side effects compared to traditional chemotherapy. The increasing incidence of CML and the demand for targeted cancer therapies are driving the growth of the dasatinib drugs market. Market Key Trends: One key trend in the dasatinib drugs market is the growing focus on precision medicine. Precision medicine aims to tailor treatment strategies based on a patient's genetic makeup, lifestyle, and environmental factors. Dasatinib, being a targeted therapy, aligns with the principles of precision medicine by selectively inhibiting specific cancer cells, thereby reducing the likelihood of adverse effects. For example, research studies have identified specific mutations in the BCR-ABL gene, which can affect the response to dasatinib treatment. This trend emphasizes the importance of personalized therapies and molecular testing in optimizing patient outcomes. PEST Analysis: - Political: Government regulations and policies related to drug approvals, intellectual property rights, and reimbursement can significantly impact the availability and affordability of dasatinib drugs. - Economic: The cost-effectiveness of dasatinib drugs compared to other treatment options, as well as healthcare expenditure and insurance coverage, can influence market growth. - Social: The increasing prevalence of cancer, especially CML, and the awareness and acceptance of targeted therapies among patients and healthcare professionals are driving market demand. - Technological: Advances in genetic testing technologies and biomarker identification are enabling the identification of patients who are likely to benefit the most from dasatinib treatment. Key Takeaways: 1: The Global Dasatinib Drugs Market Demand is expected to witness high growth, exhibiting a CAGR of 6.0% over the forecast period, due to increasing demand for targeted cancer therapies. Dasatinib's efficacy in treating CML and its ability to selectively target specific cancer cells position it as a preferred treatment option. 2: In terms of regional analysis, North America is expected to dominate the dasatinib drugs market due to the high prevalence of CML in the region and the well-established healthcare infrastructure. Asia Pacific is projected to be the fastest-growing region, driven by the increasing incidence of CML and the rising adoption of targeted therapies. 3: Key players operating in the global dasatinib drugs market include Bristol-Myers Squibb Company, Novartis International AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Cipla Ltd., Hetero Drugs Limited, Natco Pharma Limited, Dr. Reddy's Laboratories Ltd., and Aurobindo Pharma Ltd. These companies focus on research and development activities to develop innovative therapies and expand their product portfolios.

[impossibledeanmakerwombat]

Isocitrate Dehydrogenase (IDH) Inhibitors Market Growth, Trends Analysis Report 2033

The market for isocitrate dehydrogenase (IDH) inhibitors worldwide has a market value of US$ 1.7 billion in 2022 and is anticipated to grow at a CAGR of 33% from 2023 to 2033 to reach US$ 39.16 billion.

Additionally, the development of more potent and selective IDH inhibitors, as well as the expansion of their use into other cancer types, is expected to further contribute to the growth of the market. Bayer and Agios Pharmaceuticals are among the key players in the IDH inhibitors market, with their respective drugs BAY 1436032 and ivosidenib being approved by the US FDA for the treatment of IDH-mutated cancers. These drugs have shown promising results in clinical trials, including high response rates and extended survival in patients with AML.

The IDH inhibitors market is a rapidly growing field with significant potential for the treatment of several types of cancer. Continued research and development efforts, as well as the development of new drugs and treatment strategies, are expected to contribute to the growth of the market.

Get a PDF Sample with Latest Market Insights @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16847

Key Takeaways from the Market Study

The global Isocitrate dehydrogenase (IDH) inhibitors market is expected to grow with a 33% CAGR during 2023 to 2033.

Oral route of administration is expected to hold 49% of the market share in 2023 for Isocitrate dehydrogenase (IDH) inhibitors market.

North America is expected to possess 46% market share for Isocitrate dehydrogenase (IDH) inhibitors market in 2023.

Europe Isocitrate dehydrogenase (IDH) inhibitors market size is expected to possess 43% market share in 2023.

“The development of combination therapies and alternative treatment strategies is being explored to further optimize the clinical benefit of IDH inhibitors. This, in turn, is fueling the growth of IDH inhibitors market.” states an FMI analyst

Competitive Landscape

Key players in the isocitrate dehydrogenase (IDH) inhibitors market are Bayer, Agios Pharma, Daiichi Sankyo, Ohm Oncology, Celgene, Philogen S.p.A., Tragara, Aslan Pharmaceuticals, Pfizer, Inc. and Sun Pharmaceutical Industries Ltd.

Bayer is collaborating with other pharmaceutical companies, such as Agios Pharmaceuticals, in the development of IDH inhibitors. The two companies have a joint development and commercialization agreement for ivosidenib (AG-120), an oral small molecule inhibitor of the mutated IDH1 enzyme, which has been approved by the US FDA for the treatment of relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation.

Agios’ Pharma lead IDH inhibitor candidate is ivosidenib (AG-120), an oral small molecule inhibitor of the mutated IDH1 enzyme. Ivosidenib works by inhibiting the production of the oncometabolite 2-hydroxyglutarate (2-HG) and inducing differentiation of leukemia cells. Ivosidenib has been approved by the US FDA for the treatment of relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation.

For more Report Customization, connect with us at @ https://www.futuremarketinsights.com/customization-available/rep-gb-16847

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global Isocitrate dehydrogenase (IDH) inhibitors market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of Type (IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Peptides, Small Molecule, Others) Molecule Types (Monoclonal Antibody, Peptides, Small Molecules, Others) Route of Administration (Oral, Parenteral, Subcutaneous) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa)

About the Healthcare at Future Market Insights

The healthcare domain team at Future Market Insights offers expert analysis, time-efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 Billion+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis of key trends including competitive landscape, profit margin, and research development efforts.

Last few days to get reports at discounted prices, offer expires soon! Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16847

Key Segments Profiled in the Isocitrate Dehydrogenase (IDH) Inhibitors Industry Survey

Type:

IDH1 Mutant Medullary Malignant Tumor

IDH2 Mutant Medullary Malignant Tumor

Peptides

Small Molecule

Others

Molecule Types:

Monoclonal Antibody

Peptides

Small Molecules

Others

Route of Administration:

Oral

Parenteral

Subcutaneous

[itssashasharma]

Global Hemato Oncology Testing Market worth USD 4.0 billion by 2024 : Increasing Incidence of Hematologic Cancer

The study involved four major activities in estimating the current size of the hemato oncology testing market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and market sizing with industry experts across the value chain through primary research.

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study. According to the new market research report “Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) – Global Forecast to 2024″, published by MarketsandMarkets™, the Hemato Oncology Testing Market is projected to reach USD 4.0 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 14.8%. Browse in-depth TOC on “Hemato Oncology Testing Market“ 77 – Tables 29 – Figures 116 – Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=262472877 Growth in this market is driven mainly by the rising prevalence of lymphoma & myeloma cancers, growing focus on personalized medicine, and increasing collaborations for developing assays. The services segment accounted for the largest share of the product & services segment in the Hemato Oncology Testing Market in 2018. Based on product & services, the market is segmented into assay kits and services. In 2018, the services segment accounted for the largest share of the product & services segment in the Hemato Oncology Testing Market. The large share of this segment can be attributed to the rising prevalence of hematologic cancers and increasing aging population. Availability of robust infrastructure and high-end equipment for conducting hemato oncology tests are the supporting factors for clinical laboratories segment Based on end-user, the Hemato Oncology Testing Market has been segmented into four types, i.e., clinical laboratories, hospitals, academic & research institutes, and other end-users. Other end-users include CROs and pharmaceutical & biotechnological companies. Clinical laboratories accounted for the largest share of the market in 2018. This segment is expected to grow at the highest rate in the coming years. This is mainly due to the presence of advanced diagnostic equipment such as analyzers and the presence of skilled professionals to perform these tests. North America accounted for the largest share of the Hemato Oncology Testing Market in 2018 North America accounted for the largest share of the Hemato Oncology Testing Market in 2018. The large share of this segment can primarily be attributed to the high incidences of hematologic cancer, aging population, awareness regarding advanced treatment methods, and the strong presence of industry players in the region. These trends are likely to drive market growth during the forecast period. Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=262472877 Some of the leading players in the Hemato Oncology Testing Market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Germany), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), MolecularMD (Ireland), Invivoscribe, Inc. (US), Asuragen, Inc. (US), Adaptive Biotechnologies (US), ArcherDx, Inc. (US), and ARUP Laboratories Inc. (US). Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting Browse Related Reports: Molecular Diagnostics Market by Application (Infectious Disease (Hepatitis, HIV), Oncology, Genetic Testing), Technology (PCR, DNA Sequencing & NGS), End User (Hospital/Academic Laborato https://www.marketsandmarkets.com/Market-Reports/molecular-diagnostic-market-833.html Companion Diagnostics Market by Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), Technology (PCR, IHC, NGS, ISH), End User (Pharmaceutical & Biopharmaceutical

Companies, Reference Lab) – Global Forecast to 2022 https://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-155571681.html About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Contact: Mr. Shelly Singh MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: sales@marketsandmarkets.com Research Insight: https://www.marketsandmarkets.com/ResearchInsight/hemato-oncology-testing-market.asp Visit Our Website: https://www.marketsandmarkets.com Content Source: https://www.marketsandmarkets.com/PressReleases/hemato-oncology-testing.asp

[healthcareandwellness-blog]

Hypomethylating Agents Market: Introduction

Hypomethylating agents act as an essential tool in the treatment of health disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia. These are not the only available treatment options, but their use can further be integrated and optimized in a sequential treatment strategy. The hypomethylating agents are also called as DNA methyltransferase inhibitors. These have allowed the treatment of frail and higher-risk elderly patients.

Request for a sample copy of this report @ https://www.insightsandreports.com/request-sample/188

Market Dynamics

Increasing MDS cases among the population within the age group of above 50 years is one of the major reasons driving the hypomethylating agents’ market significantly. According to the American Cancer Society, the number of people who are diagnosed with MDS in the U.S. every year is unknown, but according to a study conducted by this society, around 10,000 cases are being registered in the U.S. alone, while some other estimates are much higher.

This health disorder is highly uncommon before the age of 50, and moreover, the health risks associated with disease gradually increases along with the person’s age. In the U.S., the new cases diagnosed each year are rising, as the average person’s age among the U.S. population is increasing. As the chances of disease outbreak are higher for this age group, the demand for hypomethylating agents is also predicted to grow over the forecast period.

Moreover, growing allogeneic stem cell transplants along with higher intensity approaches for the treatment of MDS, is expected to yield higher response rates and can also control the disease’s negative impact for longer times. These type of treatment facilities are increasing across the world, which will give an additional boost to the growth of hypomethylating agents market.

Hypomethylating agents market is expected to restrain, owing to the unmet need for sound treatment options among the patients. Moreover, the response rates of these agents for the control of disease’s impact is also very low, according to the National Institute of Health and American Cancer Society. These factors are expected to restrain the hypomethylating agents market significantly over the forecast period.

By Type of Treatment

By type of treatment, the hypomethylating agents market has been segmented into acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). Hypomethylating agents market for myelodysplastic syndromes is expected to have the dominant market share over the forecast period. Increasing new cases, coupled with the developing treatment options for this disorder are expected to attribute the prime share of hypomethylating agents market for myelodysplastic syndromes.

By Gender

Based on gender, the global hypomethylating agents market has been segmented into male and female. Over the forecast period, the use of hypomethylating agents for male population is projected to dominate the product use among female population. This is majorly due to the higher disease incidence chances among men, compared to women. According to the estimates by the American Cancer Society, in 2017, around 19,520 new cases of AML have been identified in the U.S. alone, out of which more than 10,670 deaths are observed, which are mostly among adults, especially among men.

By Region

North America hypomethylating agents market is expected to have the prime share in the global market over the projected period. It is majorly attributed by the increasing cases, and growing treatment facilities, along with the presence of major research organizations (NIH, ACS), and pharmaceutical companies, which are currently striving towards the research and development of new drugs to treat MDS, and AML.

Asia Pacific hypomethylating agents market is expected to witness a higher growth over the forecast period, majorly owing to the presence of key pharmaceutical companies. Manufacturing companies in this region are majorly focusing on the development of these agents, owing to the increasing cases of MDS and AML. Moreover, the governing bodies of several countries in this region are majorly focusing on the development of healthcare industry, which will provide lucrative opportunities for the hypomethylating agents market to grow over the forecast period.

Competitive Landscape

Some of the prominent players in the global hypomethylating agents market include Pfizer, Blue Point Laboratories, Actavis Pharma Company, Dr. Reddy’s Laboratories, Celgene, Cipla Limited, Otsuka Pharmaceuticals, Astex Pharmaceuticals, etc. among others.

Some key pharmaceutical companies such as Cipla Limited and Otsuka Pharmaceuticals are working constantly to get FDA approvals of the drugs developed. For instance, Cipla Limited received a final approval from the U.S. FDA for its generic drug Dacogen in November 2017.

Also, many prominent players are trying to obtain the rights from generic drug manufacturers to expand their geographic horizon in the global hypomethylating agents market. For instance, in March 2014, Otsuka Pharmaceuticals acquired rights from EISAI Inc. for the development and marketing of Dacogen in U.S., Canada, and Japan markets. 

For more information about this report @ https://www.insightsandreports.com/industry-reports/hypomethylating-agents-market

About Us:

Insights and Reports is a research and consulting group assisting the clients with 360-degree insights with real time qualitative and quantitative information. The Insights and Reports team is valued for continuous client-oriented services. Our data scientists monitor the markets pertaining to their expertise on a daily basis with the help of 150+ analysts to back them with accurate market studies.

 Contact Us:

Mr. Saby

Insights And Reports

2201 Cooperative Way #600,

Herndon, VA 20171, USA.

Tel: +1 703 574 4447

Email: sales@insightsandreports.com

[bitchyphilosopherprince]

Global Trispecific Antibody Market Key Growth Factor Analysis & Research Study 2021-2028

Bharat Book Bureau Provides the Trending Market Research Report on “Global Trispecific Antibody Market Opportunity & Clinical Trials Insight 2028”under  Life Sciences Market Research Reports Category. The report offers a collection of superior market research, market analysis, competitive intelligence and Market reports.

Global Trispecific Antibody Market Opportunity & Clinical Trials Insight 2028 Report Analysis & Data Highlights: • Research Methodology • Global Market Analysis • Global Trispecific Antibody Market Opportunity Assessment: > USD 2 Billion • US To Dominate Trispecific Antibodies Market: >70% • Market and Drug Sales Insight 2024 Till 2028 • Future Market Assessment By Indication Till 2028 • Ongoing Clinical Trials Assessment by Status, Phase and Region • Key Market Dynamics • Competitor Landscape

The advent of monoclonal antibodies has shown to greatly transform the paradigm treatment of several chronic disorders, including cancer. These modalities have shown high penetration in the market owing to their high specificity and selectivity towards the target cell. Despite their robust response in targeting diseases, the role is mainly limited due to their high molecular weight and inability to pass through blood brain barrier. Therefore, continuous research and development has been done by researchers to overcome these limitations.

Recently, the idea of trispecific antibodies has gained momentum in the market. Trispecific antibody consists of single construct which has the ability to simultaneously bind three different antigens at the same time, thus enhancing the efficacy and specificity of treatment. In addition, these have the molecular size one-third to those of monoclonal antibody which ensures high penetrability and ability to cross blood brain barrier. Due to its enhanced functionality, it is believed that trispecific antibodies will result in few side effects and doses. In addition, development of single molecule instead of three has decreased the overall cost of production as well as number of clinical trials.

Till date, no trispecific antibody has been approved for clinical use. However, a wide range of drugs are present in preclinical and clinical development which is expected to enter the market during forecast period. GTB3550 developed by GT Biopharma is one of the leading trispecific killer cell engager (TriKE) which conists of chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL5. Currently, it is being evaluated in phase-I/II clinical trial for the management of CD33 positive acute myeloid leukemia. In addition, Harpoon Therapeutics has also developed several trispecific antibodies utilizing its propertiary TriTAC (Trispecific T-cell activating construct) platform. Apart from this, several other trispecific antibodies has also been developed which are expected to gain approval during forecast period.

The higher specificity of these drugs in targeting multifactorial approach of the disease has encouraged several pharmaceutical giants to actively indulge in research and development of this sector. The pharmaceutical companies enter into alliances or partnerships which provide access to new technologies, and also attract new invesors. The major companies competing in global trispecific antibody market are Sanofi, Numab Therapeutics, Harpoon Therapeutics, and CStone Pharmaceuticals.

At present, researchers have identified the role of trispecific antibodies in cancer as well as HIV. However, with the advancement in science and encouraging response of these modalities it is analyzed that trispecific antibodies will also be utilized in other therapeutic conditions. By segment, cancer is expected to dominate the market attributing mainly to large number of products in clinical trials. Moreover in coming years, the research will be mainly oriented towards cancer therapeutics attributing mainly to their high prevalence and unavailability of effectively curing drugs. The unmet need for the development of targeted therapy and increase in research and development funding by government as well as private sector will also drive the future of novel trispecific antibodies in the management of cancer.

Currently, the global trispecific antibody market is present at nascent stage due to no product approval. However, it is expected that trispecific antibody is anticipated to grow with high growth rates during forecast period. The market will be mainly driven by the rapid increase in the geriatric population which possesses significant risk of developing cancer. Moreover, the unavailability of effectively curing cancer drugs also demands for the development of targeted therapy which will also boost the market. Keeping in mind the high adoption rates of novel cancer therapies, it is expected that US will dominate the market for next 5-7 years. In addition to this, high awareness among the population, presence of large biopharmaceutical sector will also propel the growth of market in this region.

Browse our full report with Table of Content : https://www.bharatbook.com/report/1025005/global-trispecific-antibody-market-opportunity-clinical-trials-insight

About Bharat Book Bureau: Bharat Book is Your One-Stop-Shop with an exhaustive coverage of 4,80,000 reports and insights that includes latest Market Study, Market Trends & Analysis, Forecasts Customized Intelligence, Newsletters and Online Databases. Overall a comprehensive coverage of major industries with a further segmentation of 100+ subsectors.

Contact us at: Bharat Book Bureau Tel: +91 22 27810772 / 27810773 Email: poonam@bharatbook.com Website: www.bharatbook.com

[techsciresearch]

Saudi Arabia Poultry Market to Witness Steady Growth till 2026 | TechSci Research

Strong economic growth and the growing food requirements is expected to drive the demand for Saudi Arabia Poultry market in the forecast period.

According to TechSci Research report, “Saudi Arabia Poultry Market By Type (Broiler, Eggs, Others) By Product Type (Raw, Chilled, Frozen) By Nature (Organic, Conventional) By Distribution Channel (Supermarkets/Hypermarkets, Traditional Stores, Specialized Stores, Online, Others), By region, Company Forecast & Opportunities, 2026”, The Saudi Arabia Poultry market is expected to witness steady growth in the forecast period. The rapid urbanization of the people to live in better conditions and search for employment opportunities is contributing to the growth of the poultry market and enhancing the demand for processed and unprocessed chicken and eggs.

Support of the leading authorities for the development of the poultry market in form of relaxation in income tax, direct subsidies for select food items, interest-free loans, and duty-free imports of raw materials. The leading authorities are providing support to the local manufacturers and taking significant measures to reduce the mortality rate of the bird. An increase in the preference of the consumers for low-fat and high-protein-containing food items is fostering the growing demand of the market. The development of the trade channel and the technological advancements to keep the freshness of the food items and aid in increasing the shelf life of the edible animal food items is fostering the growth of the poultry market.

The increase in the demand for frozen and chilled food items is influencing the demand for poultry-based products in the region. The high demand for the consumption of poultry-based products and the unavailability of quality animal-based edible items in the country and the need to import the animal-based food items are creating lucrative opportunities for the growth of the poultry market. The Saudi government is making heavy investments for the infrastructural development of the country in order to develop the retail and hospitality sector in the country. Under the Saudi Vision 2030, the development of the tourism industry to attract more tourists to the country for religious and other purposes, the government is aiming to develop the poultry sector to meet the growing food requirements.

The COVID-19 outbreak across the world which has been declared as a pandemic by World Health Organization has affected several countries adversely. Leading authorities of Saudi Arabia imposed lockdown restrictions and released a set of precautionary measures to contain the spread of novel coronavirus. The coronavirus pandemic hit the economic status of the country which negatively impacted the growth of the industry. Disruption in the supply chain was observed which adversely affected the supply of raw materials around the country.

However, the growing cost of the poultry feeds and strict quality checks and norms may hamper the Saudi Arabia Poultry market growth in the forecast period.

Browse XX Figures spread through XX Pages and an in-depth TOC on "Saudi Arabia Poultry Market”.

https://www.techsciresearch.com/report/saudi-arabia-poultry-market/7726.html

Saudi Arabia Poultry market is segmented into type, product type, nature, distribution channel, regional distribution, and company. Based on the type, the market can be divided into broiler, eggs, and others. The broiler segment is expected to witness growth in the next five years, 2022-2026. The rise in the demand for whole chicken and its parts and the increasing affordability of the consumers is fostering the growth of this segment. The Hajj pilgrimage attracts a lot of tourists in the country which is expected to fuel the demand and rapid development of the catering service market.  The rise in the development of the construction industry and the liability of the company to provide three meals a day is contributing to the growth of the poultry market as the normal diet in Saudi Arabia includes the portion of animal meat or products.

Almarai Saudi Arabia, Al-Watania Poultry Company, Al-Fakeih Poultry, Al-Berri United Food Co. Ltd, Alwadi Poultry Farms Ltd, Co., Arabian Agricultural Services Company, Arabian Farms Dev.Co.Ltd., Alsalamah Almotatawera Co, BRF S.A, Bayle S.A., Cargill Incorporated, Cherkizovo Group are the leading players operating in Saudi Arabia Poultry market. Manufacturers are increasingly focusing on research and development process to fuel higher growth in the market. To meet evolving customer demand with respect to better efficiency and durability, several Poultry manufacturers are coming up with their technologically advanced offerings.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7726

Customers can also request for 10% free customization on this report.

“Development of the online commerce channels to improve the reach of products and brand image, the market players are investing huge amounts. The offering of attractive discounts and the facility for home delivery and online payment gateways ate contributing to the growth of the market. The market players are adopting advanced technologies such as 3-D imaging systems to determine the way for optimal cuts and minimize the per-unit cost for poultry processing. The use of latest technologies and the development of efficient distribution channels is expected to propel the growth of the Poultry market till 2026” said Mr. Karan Chechi, Research Director with TechSci Research, a global research-based management consulting firm.

“Saudi Arabia Poultry Market By Type (Broiler, Eggs, Others) By Product Type (Raw, Chilled, Frozen) By Nature (Organic, Conventional) By Distribution Channel (Supermarkets/Hypermarkets, Traditional Stores, Specialized Stores, Online, Others), By region, Company Forecast & Opportunities, 2026” has evaluated the future growth potential of Saudi Arabia Poultry market and provided statistics & information on market size, shares, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the of Saudi Arabia Poultry market.

Browse Related Reports:

Global Organic Food Market By Product Type (Organic Meat, Poultry & Dairy; Organic Fruits & Vegetables; Organic Processed Food; Organic Bread & Bakery; Organic Beverages; Organic Processed Food and Others), By Distribution Channel Type (Hypermarket/Supermarket, Speciality Stores, Departmental Stores, Online and Others (Spices, Pulses, Cereals &Food Grains etc.), By Region, Competition, Forecast Opportunities, 2026

https://www.techsciresearch.com/report/organic-food-market/4401.html

Vietnam Frozen Food Market By Category, ((Ready-to-Eat, Ready-to-Cook & Others (Raw Meat, Raw Vegetables, Raw Fruit, etc.)), By Product Type (Frozen Meat, Poultry, & Seafood, Frozen Snacks, Frozen Fruits & Vegetables, Frozen Desserts, Frozen Cooked Ready Meals, & Others), By Distribution Channel (Departmental Stores, Specialty Stores, Supermarket/Hypermarket, Online & Others (Convenience Stores, Direct Sales, etc.)), By Region, Competition, Forecast Opportunities, 2026F

https://www.techsciresearch.com/report/vietnam-frozen-food-market/2942.html

Global Leukemia Therapeutics Market By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Gender (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html

Global Outpatient Hospital Services Market By Services (Treatment Services, Diagnostic Tests, Minor Surgical Procedures, Others) By Type (Emergency Department, Urgent Care Centers, Primary Care Clinics, Specialized Outpatient Clinics, Others) By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/outpatient-hospital-services-market/7732.html

Saudi Arabia Seafood Market By Product (Fish, Shrimp, Crab, Lobster, Others) By Type (Raw, Frozen, Processed) By Application (Retail, Institution Sales and Food Service) By Distribution Channel (Supermarket/Hypermarket, Departmental Stores, Specialized Stores, Online, Others), Company Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/saudi-arabia-seafood-market/7727.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

[techscimarketresearch]

Saudi Arabia Poultry Market to Witness Steady Growth till 2026 | TechSci Research

Strong economic growth and the growing food requirements is expected to drive the demand for Saudi Arabia Poultry market in the forecast period.

According to TechSci Research report, “Saudi Arabia Poultry Market By Type (Broiler, Eggs, Others) By Product Type (Raw, Chilled, Frozen) By Nature (Organic, Conventional) By Distribution Channel (Supermarkets/Hypermarkets, Traditional Stores, Specialized Stores, Online, Others), By region, Company Forecast & Opportunities, 2026”, The Saudi Arabia Poultry market is expected to witness steady growth in the forecast period. The rapid urbanization of the people to live in better conditions and search for employment opportunities is contributing to the growth of the poultry market and enhancing the demand for processed and unprocessed chicken and eggs.

Support of the leading authorities for the development of the poultry market in form of relaxation in income tax, direct subsidies for select food items, interest-free loans, and duty-free imports of raw materials. The leading authorities are providing support to the local manufacturers and taking significant measures to reduce the mortality rate of the bird. An increase in the preference of the consumers for low-fat and high-protein-containing food items is fostering the growing demand of the market. The development of the trade channel and the technological advancements to keep the freshness of the food items and aid in increasing the shelf life of the edible animal food items is fostering the growth of the poultry market.

The increase in the demand for frozen and chilled food items is influencing the demand for poultry-based products in the region. The high demand for the consumption of poultry-based products and the unavailability of quality animal-based edible items in the country and the need to import the animal-based food items are creating lucrative opportunities for the growth of the poultry market. The Saudi government is making heavy investments for the infrastructural development of the country in order to develop the retail and hospitality sector in the country. Under the Saudi Vision 2030, the development of the tourism industry to attract more tourists to the country for religious and other purposes, the government is aiming to develop the poultry sector to meet the growing food requirements.

The COVID-19 outbreak across the world which has been declared as a pandemic by World Health Organization has affected several countries adversely. Leading authorities of Saudi Arabia imposed lockdown restrictions and released a set of precautionary measures to contain the spread of novel coronavirus. The coronavirus pandemic hit the economic status of the country which negatively impacted the growth of the industry. Disruption in the supply chain was observed which adversely affected the supply of raw materials around the country.

However, the growing cost of the poultry feeds and strict quality checks and norms may hamper the Saudi Arabia Poultry market growth in the forecast period.

Browse XX Figures spread through XX Pages and an in-depth TOC on "Saudi Arabia Poultry Market”.

https://www.techsciresearch.com/report/saudi-arabia-poultry-market/7726.html

Saudi Arabia Poultry market is segmented into type, product type, nature, distribution channel, regional distribution, and company. Based on the type, the market can be divided into broiler, eggs, and others. The broiler segment is expected to witness growth in the next five years, 2022-2026. The rise in the demand for whole chicken and its parts and the increasing affordability of the consumers is fostering the growth of this segment. The Hajj pilgrimage attracts a lot of tourists in the country which is expected to fuel the demand and rapid development of the catering service market.  The rise in the development of the construction industry and the liability of the company to provide three meals a day is contributing to the growth of the poultry market as the normal diet in Saudi Arabia includes the portion of animal meat or products.

Almarai Saudi Arabia, Al-Watania Poultry Company, Al-Fakeih Poultry, Al-Berri United Food Co. Ltd, Alwadi Poultry Farms Ltd, Co., Arabian Agricultural Services Company, Arabian Farms Dev.Co.Ltd., Alsalamah Almotatawera Co, BRF S.A, Bayle S.A., Cargill Incorporated, Cherkizovo Group are the leading players operating in Saudi Arabia Poultry market. Manufacturers are increasingly focusing on research and development process to fuel higher growth in the market. To meet evolving customer demand with respect to better efficiency and durability, several Poultry manufacturers are coming up with their technologically advanced offerings.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7726

Customers can also request for 10% free customization on this report.

“Development of the online commerce channels to improve the reach of products and brand image, the market players are investing huge amounts. The offering of attractive discounts and the facility for home delivery and online payment gateways ate contributing to the growth of the market. The market players are adopting advanced technologies such as 3-D imaging systems to determine the way for optimal cuts and minimize the per-unit cost for poultry processing. The use of latest technologies and the development of efficient distribution channels is expected to propel the growth of the Poultry market till 2026” said Mr. Karan Chechi, Research Director with TechSci Research, a global research-based management consulting firm.

“Saudi Arabia Poultry Market By Type (Broiler, Eggs, Others) By Product Type (Raw, Chilled, Frozen) By Nature (Organic, Conventional) By Distribution Channel (Supermarkets/Hypermarkets, Traditional Stores, Specialized Stores, Online, Others), By region, Company Forecast & Opportunities, 2026” has evaluated the future growth potential of Saudi Arabia Poultry market and provided statistics & information on market size, shares, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the of Saudi Arabia Poultry market.

Browse Related Reports:

Global Organic Food Market By Product Type (Organic Meat, Poultry & Dairy; Organic Fruits & Vegetables; Organic Processed Food; Organic Bread & Bakery; Organic Beverages; Organic Processed Food and Others), By Distribution Channel Type (Hypermarket/Supermarket, Speciality Stores, Departmental Stores, Online and Others (Spices, Pulses, Cereals &Food Grains etc.), By Region, Competition, Forecast Opportunities, 2026

https://www.techsciresearch.com/report/organic-food-market/4401.html

Vietnam Frozen Food Market By Category, ((Ready-to-Eat, Ready-to-Cook & Others (Raw Meat, Raw Vegetables, Raw Fruit, etc.)), By Product Type (Frozen Meat, Poultry, & Seafood, Frozen Snacks, Frozen Fruits & Vegetables, Frozen Desserts, Frozen Cooked Ready Meals, & Others), By Distribution Channel (Departmental Stores, Specialty Stores, Supermarket/Hypermarket, Online & Others (Convenience Stores, Direct Sales, etc.)), By Region, Competition, Forecast Opportunities, 2026F

https://www.techsciresearch.com/report/vietnam-frozen-food-market/2942.html

Global Leukemia Therapeutics Market By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Gender (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html

Global Outpatient Hospital Services Market By Services (Treatment Services, Diagnostic Tests, Minor Surgical Procedures, Others) By Type (Emergency Department, Urgent Care Centers, Primary Care Clinics, Specialized Outpatient Clinics, Others) By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/outpatient-hospital-services-market/7732.html

Saudi Arabia Seafood Market By Product (Fish, Shrimp, Crab, Lobster, Others) By Type (Raw, Frozen, Processed) By Application (Retail, Institution Sales and Food Service) By Distribution Channel (Supermarket/Hypermarket, Departmental Stores, Specialized Stores, Online, Others), Company Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/saudi-arabia-seafood-market/7727.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

[kenresearch1]

Top 3 US Pharmaceutical Companies and Their Strategies in US Acute Myeloid Leukemia Market

Buy Now

US Acute Myeloid Leukemia Market is growing due to advancement in treatment approaches, increase healthcare costs and expenditure, growing investments in Research and Development, and a constant growth in population.

Story Outline

Pfizer Inc.- An American multinational company with the highest annual revenue of around 100 billion US$ in 2022 in the drug market. The company has made significant contributions to the US Acute Myeloid Leukemia Market through a sophisticated, robust, agile manufacturing infrastructure and investment in research and development.

Brystol Myers Squibb- One of the largest American pharmaceutical companies which consistently ranks on the Fortune 500 list of the largest US corporations. The company’s mission is to discover, develop, and deliver innovative medicines that help patients as well as prevail over serious diseases.

Novartis AG- The company with the fourth-largest revenue in the drug market which is focused to deliver high-value medicine that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches.

The US Acute Myeloid Leukemia Market is expected to grow at CAGR of 10.5% in the forecast period 2022-2028.

The Acute Myeloid Leukemia Market of US is driving growth at an amazing level. This surge is a result of advancement in treatment approaches, increases healthcare costs and expenditure, growing investments in Research and Development, and a constant growth in population.

Various pharmaceutical companies are actively shaping this growing market with their strategies and innovations.

This article provides an in-depth look at major pharmaceutical companies with their strategies and innovations.

1.Pfizer Inc.

Click here: To know more about Pfizer Inc.

Pfizer Inc. is an American multinational pharmaceutical company and headquartered at The Spiral in Manhattan, New York City. The company has made significant contributions to the US Acute Myeloid Leukemia Market through a sophisticated, robust, agile manufacturing infrastructure and investing in research and development.

The company employs more than 30,000 employees worldwide, have 35+ manufacturing sites, 300+ external suppliers, and have reached more than 180 countries. Pfizer tops the list of drug market by achieving a revenue of approx. 100 billion USD in 2022.

Pfizer has made significant contributions to the US acute Myeloid Leukemia Market. Some notable contributions are, in April 2017, the development and approval of a targeted therapy called “Rydapt”, which is an oral kinase inhibitor that targets multiple enzymes, including FLt3, which is often mutated in AML patients. The drug was approved by FDA in April 2017 for use in combination with Chemotherapy.

Furthermore, MYLOTARG is approved in combination with daunorubicin and cytarabine for the treatment of patients aged 15 and above with previously untreated, de novo, CD33-positive acute myeloid leukemia (AML), except Acute Promyelocytic Leukemia (APL).

The company’s purpose is “Breakthroughs that change patients' lives—fuels everything we do and reflects our passion for building on our legacy as one of the greatest contributors of good to the world.

The company says that its purpose ensures that its patients remain at the center of all that they do. They live with their purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to their medicines.

Pfizer believes in growing partnerships with innovators to initiate forward great science and continually seek new partners that are actively researching bold scientific ideas. In December 2022, Pfizer announced its collaboration with Gero’s machine learning technology platform to discover potential therapeutic targets for fibrotic using large-scale human-based data.

Pfizer’s continuous clinical trials and collaboration with healthcare institutions and research organizations has majorly contributed in advancing Acute Myeloid Leukemia Market and the development of novel treatment strategies.

2.Bristol Myers Squibb

Click here: To Download a Sample Report

The Bristol Myers Squibb Company, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. BMS is one of the world’s largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest US corporations.

The company employs more than 34,000 across more than 86 locations worldwide. The company’s revenue in 2022 was approximately 46 bn USD.

Their mission is to discover, develop, and deliver innovative medicines that help patients as well as prevail over serious diseases. Bristol believes in the power of science to address some most challenging diseases of today's world.

Bristol Myers is majorly known for its contributions to oncology, and immunology and its involvement in Acute Myeloid Leukemia Market with its broader focus on cancer treatments.

The significant development of BMS can be noted from June 2021, Bristol Myers Squibb received approval from European Commission for Onureg, a Frontline oral maintenance therapy for adult patients with acute Myeloid Leukemia who achieved their first complete remission (CR) or CR with incomplete blood count recovery following intensive induction chemotherapy. Onureg is expected to increase sales and product revenue, thereby increasing the US Acute Myeloid Leukemia Market growth.

Furthermore, the strategic cooperation between Evotec and Bristol Myers Squibb has grown in order to create a pipeline for programs addressing more neurological illnesses. In order to find altering therapies for a variety of neurodegenerative disorders, the firms started working together in 2016. The eight-year extension is intended to strengthen the strategic partnership even more.

3.Novartis AG

Click Here : To Download a Custom Report

Novartis AG is a healthcare company that majorly focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical and eye care products. Novartis offers generic medicines and biosimilars through Sandoz. The company conducts its research through The Novartis Institute for Biomedical Research (NIBR).

Novartis is one of the largest pharmaceutical companies in the world and the fourth largest by revenue in 2022, which was approx. 50.500 billion USD.

The company is functioning in more than 150 locations with around 1,10,000 employees working worldwide.

Novartis's strategy as a focused medicines company is to deliver high-value medicine that alleviates society’s greatest disease burdens through technology leadership in R&D an novel access approaches.

Novartis contribution to Acute Myeloid Leukemia Market includes, FDA approval of Novartis Scemblix (asciminib), with novel mechanism of action for the treatment of Leukemia in October,2021.

Furthermore, through their open approach Novartis is focusing on new technologies to develop next generation therapeutics. Currently, Novartis is working with Orionis Bioscience to find new targets at a genome-wide scale.

By combining development and drug discovery with innovation, they aim to achieve tenuous targets and to launch novel small molecule therapy for Acute Myeloid Leukemia patients more quickly. Thus driving a steered growth for the US Acute Myeloid Leukemia Market.

[kritikarehani]

Acute Myeloid Leukemia Market Size, Share, Trends, Epidemiology and Market Forecast 2030

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous malignancy characterized through clonal proliferation and impaired differentiation of myeloid precursors with various outcomes. Quickest-growing cancer happens when the bone marrow begins to form cells that have not yet absolutely matured as blasts. These cells crowd the bone marrow, stopping it from making normal blood cells and leukemia starts to crowd out the normal white blood cells, crimson blood cells, and platelets that the frame desires. In Acute myeloid leukemia, the bone marrow additionally makes strange crimson cells and platelets. As consequence, the blood cells do not develop, and it gets hard to ward off infections.

Acute Myeloid Leukemia Signs and Symptoms

The symptoms of acute myeloid leukemia generally expand over a week and become an increasing number severely. Signs can include anemia, light skin, constant tiredness, joint infections, frequent bleeding, bone pain, and others.

Acute Myeloid Leukemia Epidemiology

Acute Myeloid Leukemia accounts for <3% of all cancer, and 25% of all leukemia in adults. Worldwide, the incidence of Acute Myeloid Leukemia is reported to be highest in the US, Australia, and Western Europe. The incidence has been near stable over the last years. Incidence continuously shows 2 peaks in occurrence in early childhood and later adulthood. From 2000 to 2003, the US incidence rate in people aged <65 years was only 1.8 per 100,000 persons, whereas the incidence rate in people aged 65 years was 17 per 100,000 persons.

The Acute Myeloid Leukemia incidence rate of 3.7 per 100,000 inhabitants in Europe with a 5-year survival rate of 19%. A cross-national study using US and England data found that the overall risk of mortality for Acute Myeloid Leukemia was 23% lower in England compared to that in the US. However, survival difference was similar in subgroups of sex and age at diagnosis.

According to a study, the yearly average incidence rate of leukemia was 3.68/105 during 2003-2007 in Nanjing. There were no significant differences in gender, the incidence rate was the highest in the group aged 80~ years.

Acute Myeloid Leukemia Treatment Options

Acute Myeloid Leukemia is common leukemia affecting adults and poses a major medical challenge with increased mortality and morbidity. Once diagnosed, the treatment needs to start as quickly as possible. The treatment depends on age, risk factors, and the sub-types of Acute Myeloid Leukemia.

The aim of treatment for Acute Myeloid Leukemia is to cure it and achieve remission of leukemia cells. Traditionally, the standardized treatment was chemotherapy which can be divided into intensive chemotherapy and non-intensive. The intensive chemotherapies are two phases of remission induction followed by post-remission consolidation-based therapy. The induction therapy includes drugs such as Cytarabine, Daunorubicin, Idarubicin, and Fludarabine either alone or in combinatorial doses. Consolidation therapy is presented in such cases where induction therapy failed to work, with drugs such as Etoposide, Amsacrine, and Mitoxantrone.

Acute Myeloid Leukemia Market

FLT3 Inhibitors such as Midostaurin and Gilteritinib; IDH Inhibitors such as Enasidenib and Ivosidenib; and Hedgehog pathway inhibitor, such as Glasdegib; BCL-2 inhibitor such as Venetoclax have recently entered the Acute Myeloid Leukemia market as promising targeted therapies with specific genetic mutations. As the first directed agent that works very well in the elderly population with Acute Myeloid Leukemia, Venetoclax and Glasdegib has opened possibilities in the world of targeted therapy. Gilteritinib, Enasidenib, and Ivosidenib were approved explicitly for relapsed and refractory Acute Myeloid Leukemia, with specific genetic mutations. This spell of new drug approvals has altered the Acute Myeloid Leukemia Market and provided new opportunities.

Various companies such as Actinium Pharmaceuticals, AVEO Oncology, Biodesix, Daiichi Sankyo, BioSight, Helsinn Healthcare, Rafael Pharmaceuticals, Otsuka Pharmaceutical, Cyclacel Pharmaceuticals, and others are developing effective therapies, which contribute to the market size of Acute Myeloid Leukemia.  

There are many competitors in the development phase for the treatment of AML such as Iomab-B CD45 and Actimab-A CD33 (Actinium Pharmaceuticals), Ficlatuzumab (AVEO Oncology and Biodesix), Devimistat (Rafael Pharmaceuticals), BST236 (BioSight), Bemcentinib (BerGenBio), Pracinostat (Helsinn Healthcare) and others.

[kennethresearch]

Global Asparaginase Market, June 2021 Report On Analysis 2021, Size, Top Players with Share, Total Revenues, Product Scope, Business Development and Opportunities till 2030

In a recently published report, Global Asparaginase Market report for till 2030. The report further now discusses; the various strategies to be adopted or being adopted by the business players across the globe at various levels in the value chain. In view of the global economic slowdown, we further estimated that China, India, Japan and South Korea to recover fastest amongst all the countries in the Asian market. Germany, France, Italy, Spain to take the worst hit and this hit is expected to regain 25% by the end of 2021- Positive Growth in the economic demand and supply.

U S Market recovers fast; In a release on May 4th 2021, the U.S. Bureau and Economic Analysis and U.S. Census Bureau mention the recovery in the U.S. International trade in March 2021. Exports in the country reached $200 billion, up by $12.4 billion in Feb 2021. Following the continuous incremental trend, imports tallied at $274.5 billion, picked up by $16.4 billion in Feb 2021. However, as COVID19 still haunts the economies across the globe, year-over-year (y-o-y) average exports in the U.S. declined by $7.0 billion from March 2020 till March 2021 whilst imports increased by $20.7 billion during the same time. This definitely shows how the market is trying to recover back and this will have a direct impact on the Healthcare/ICT/Chemical industries, creating a huge demand for Global Asparaginase Market products.

Get Sample Reports Here – https://www.kennethresearch.com/sample-request-10306407

It is also anticipated to grow on account of the growing demand for chemicals from the end users, backed by the increasing consumption of chemicals across different industries and the rising need for advanced chemicals. In India, the production of major chemicals and petrochemicals during the period 2020-2021 was close to 12000 thousand MT. Additionally, between the period 2015-16 and 2019-20, the production of the chemicals and petrochemicals in the nation grew at a CAGR of close to 6%.

Global Asparaginase Market is valued approximately at USD XXX million in 2018 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2019-2026. Asparaginase is an enzyme which catalzes the hydrolysis of l-asparagine to l-aspartic acid and ammonia. Asparaginase products are isolated from different types of bacteria, namely Escherichia coli and Erwinia chrysanthemi. They inhibit protein synthesis in tumor cells by depriving them of the amino acid asparagine. These are used widely in Healthcare industry and Food manufacturing industry as a medication. It is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin’s lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available. As Asparaginase was approved for medical use in the United States in 1978. It is also on the World Health Organization’s List of Essential Medicines, the most effective and safe medicines needed in a health system. Asparaginase is used in the food manufacturing to reduce the formation of acrylamide. Acrylamide is a carcinogen in the starch containing food products such as biscuits and snacks. Thus, the rapidly growing healthcare and food manufacturing industry increase the demand for Asparaginase during the forecast period. As the Food and drinks market in Europe contributed to be the largest manufacturing sector in 2017 with a turnover of USD 1222 billion. The same sector invested USD 3.12 billion in research & development in 2017 which shows a positive sign in the market growth. Further, the rising investments of the market players for the research and development and production of Asparaginase according to the regulatory specification due to the rise in demand further fuels the market growth. However, the side effects of Asparaginase on human body such as mild bone marrow suppression, pancreatitis, anticoagulant factor resulting in stroke and bleeding hinders the market growth.

The regional analysis of global Asparaginase market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the dominant pharmaceutical industry in the region which is the major industry which uses Asparaginase enzyme. Further rising cases of Leukemia in the region propel the market growth. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2019-2026. Factors such as increasing population along with increasing disposable income coupled with growing food manufacturing industry would create lucrative growth prospects for the Asparaginase market across Asia-Pacific region.

Major market player included in this report are: Jazz Pharmaceuticals Plc Shire Plc Medac GmbH Kyowa Hakko Kirin Co., Ltd. Qianhong Bio-pharma Taj Pharmaceuticals Mingxing Pharma Exova SL Pharma Inc United Biotech Pvt. Ltd. Novus Biologicals The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below: By Type: Escherichia Coli Erwinia Chrysanthemi Pegylated By Application: Healthcare Food Industry Others By Region: North America U.S. Canada Europe UK Germany Asia Pacific China India Japan Latin America Brazil Mexico Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2016, 2017 Base year – 2018 Forecast period – 2019 to 2026

Target Audience of the Global Asparaginase Market in Market Study:

Key Consulting Companies & Advisors Large, medium-sized, and small enterprises Venture capitalists Value-Added Resellers (VARs) Third-party knowledge providers Investment bankers Investor

Download Sample Reports Here – https://www.kennethresearch.com/sample-request-10306407

The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook

Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analys  & Opportunity Outlook

Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook

Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Kenneth Research

Email : Sales@kennethresearch.com

Phone: +1 313 462 0609

[marketinformation]

Hematologic Malignancies Market 2021: CAGR of 10.68% With Top Countries Data, Latest Trends, Market Size, share, Global Industry Analysis and Forecast by 2027

"Hematologic Malignancies Market is valued at USD 43929.55 Million in 2018 and expected to reach USD 89380.09 Million by 2025 with the CAGR of 10.68% over the forecast period."

Rising incidence of blood cancer driving the growth of hematologic malignancies market.

Scope of the Hematologic Malignancies Market Report:

Hematological malignancies are the kinds of cancer affecting blood, bone marrow and lymph nodes. It is also called as hematological disease. The many distinct sorts of mature blood cells, like red blood cells for carrying oxygen, white blood cells for immune protection and platelets for wound clotting. It is arise from hematopoietic stem and progenitor cells in the bone marrow.

Continue …. @ https://brandessenceresearch.com/healthcare/global-hematologic-malignancies-market-size

Hematologic malignancies are cancers that begin in these cells, and are subdivided according to which type of blood cell is affected such as Lymphoblastic or lymphocytic and Myelogenous or myeloid . A malignancy in the lymphoid lineage that includes white blood cells such as T lymphocytes and B lymphocytes.

For examples include acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphomas and multiple myeloma. And, malignancy in the myeloid lineage that includes precursor cells to red blood cells, platelets and white blood cells such as granulocytes. For examples, acute myelogenous leukemia and chronic myelogenous leukemia.

Hematologic malignancies Companies:

Hematologic malignancies market report covers prominent playersare,

Pfizer     Inc

F.     Hoffmann-LA Roche Ltd

Sanofi

Bristol-Myers     Squibb Company

AbbVieInc

Novartis     AG

GlaxoSmithKline     PLC

Celgene     Corporation Johnson & Johnson Services, Inc

Takeda     Pharmaceutical Company

Others.

Hematologic malignancies are cancers that begin in these cells, and are subdivided according to which type of blood cell is affected such as my elogenous or myeloid. A malignancy in the myeloid lineage that includes precursor cells to red blood cells, platelets and white blood cells such as granulocytes. The most commonly diagnosed blood cancers are non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, acute lymphoblastic leukemia and multiple myeloma.

Get Free Sample PDF Copy of Latest Research on Hematologic Malignancies Market 2021 before the purchase @ https://brandessenceresearch.com/requestSample/PostId/1023?utm_source=AR

Hematologic malignancies market report is segmented on the basis of type, therapy and by regional & country level. Based upon type, Hematologic malignancies market is classified into Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma and Others. Based upon therapy, Hematologic malignancies market is classified into Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation and Others.

Hematologic malignancies Market Segmentation –

By Type: - Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma, Others

By Therapy: - Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, Others

By Regional & Country Analysis:

North America

o   U.S.

o   Canada

 U.K.

 France

 Germany

 Italy

 China

 Japan

 India

 Southeast      Asia

 Brazil

 Mexico

 GCC

 Africa

 Rest      of Middle East and Africa

About Brandessence Market Research Inc.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact Us:

Alan Ruffalo

Corporate Sales: +44-2038074155

Email: sales@brandessenceresearch.com

Web: https://brandessenceresearch.com/

[impossibledeanmakerwombat]

Hematopoietic Stem Cell Transplantation Market 2023 Growth, COVID Impact, Trends Analysis Report 2033

A recently published study by FMI expects the global hematopoietic stem cell transplantation market to augment at an 8% CAGR from 2023 to 2033. By the end of the said assessment period, a valuation of US$ 15 Billion is expected for the market. The hematopoietic stem cell transplantation market has grown fast in recent years and is expected to develop substantially over the projected period. According to the GLOBOCAN 2018 report, the global incidence of leukaemia in 2018 was predicted to be 437,033 new cases and about 309,006 deaths.

Request Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16462

According to the World Health Organization (WHO), more than 2000 cord blood hematopoietic stem cell transplants are performed each year (WHO). Hematopoietic stem cells can be found in bone marrow and blood (HSCs).

Key Segments Profiled in the Hematopoietic Stem Cell Transplantation Market Industry Survey

By Transplant Type:

Allogeneic

Autologous

By Indication:

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Hodgkin Lymphoma

Non-Hodgkin Lymphoma

Multiple Myeloma

Other Non-Malignant Disorders

By Application:

Bone Marrow Transplant

Peripheral Blood Stem Cells Transplant

Cord Blood Transplant

[itssashasharma]

Global Hemato Oncology Testing Market worth $ 4.0 billion by 2024 : Increasing Incidence of Hematologic Cancer

The study involved four major activities in estimating the current size of the hemato oncology testing market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and market sizing with industry experts across the value chain through primary research.

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study. According to the new market research report “Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) – Global Forecast to 2024″, published by MarketsandMarkets™, the Hemato Oncology Testing Market is projected to reach USD 4.0 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 14.8%. Browse in-depth TOC on “Hemato Oncology Testing Market“ 77 – Tables 29 – Figures 116 – Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=262472877 Growth in this market is driven mainly by the rising prevalence of lymphoma & myeloma cancers, growing focus on personalized medicine, and increasing collaborations for developing assays. The services segment accounted for the largest share of the product & services segment in the Hemato Oncology Testing Market in 2018. Based on product & services, the market is segmented into assay kits and services. In 2018, the services segment accounted for the largest share of the product & services segment in the Hemato Oncology Testing Market. The large share of this segment can be attributed to the rising prevalence of hematologic cancers and increasing aging population. Availability of robust infrastructure and high-end equipment for conducting hemato oncology tests are the supporting factors for clinical laboratories segment Based on end-user, the Hemato Oncology Testing Market has been segmented into four types, i.e., clinical laboratories, hospitals, academic & research institutes, and other end-users. Other end-users include CROs and pharmaceutical & biotechnological companies. Clinical laboratories accounted for the largest share of the market in 2018. This segment is expected to grow at the highest rate in the coming years. This is mainly due to the presence of advanced diagnostic equipment such as analyzers and the presence of skilled professionals to perform these tests. North America accounted for the largest share of the Hemato Oncology Testing Market in 2018 North America accounted for the largest share of the Hemato Oncology Testing Market in 2018. The large share of this segment can primarily be attributed to the high incidences of hematologic cancer, aging population, awareness regarding advanced treatment methods, and the strong presence of industry players in the region. These trends are likely to drive market growth during the forecast period. Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=262472877 Some of the leading players in the Hemato Oncology Testing Market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Germany), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), MolecularMD (Ireland), Invivoscribe, Inc. (US), Asuragen, Inc. (US), Adaptive Biotechnologies (US), ArcherDx, Inc. (US), and ARUP Laboratories Inc. (US). Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting Browse Related Reports: Molecular Diagnostics Market by Application (Infectious Disease (Hepatitis, HIV), Oncology, Genetic Testing), Technology (PCR, DNA Sequencing & NGS), End User (Hospital/Academic Laborato https://www.marketsandmarkets.com/Market-Reports/molecular-diagnostic-market-833.html Companion Diagnostics Market by Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), Technology (PCR, IHC, NGS, ISH), End User (Pharmaceutical & Biopharmaceutical Companies, Reference

Lab) – Global Forecast to 2022 https://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-155571681.html About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Contact: Mr. Shelly Singh MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: sales@marketsandmarkets.com Research Insight: https://www.marketsandmarkets.com/ResearchInsight/hemato-oncology-testing-market.asp Visit Our Website: https://www.marketsandmarkets.com Content Source: https://www.marketsandmarkets.com/PressReleases/hemato-oncology-testing.asp